Related Experiment Video
Updated: Jun 18, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Xenotropic murine leukemia virus-related virus is susceptible to AZT
Ryuta Sakuma1, Toshie Sakuma, Seiga Ohmine
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55906, USA.
Abstract:
The xenotropic murine leukemia virus-related virus (XMRV) is a human retrovirus, recently isolated from tissues of prostate cancer patients with impaired RNase L activity. In this study, we evaluated 10 licensed anti-HIV-1 compounds for their activity against XMRV, including protease inhibitors (PI), nucleoside reverse transcriptase (RT) inhibitors (NRTI), non-nucleoside RT inhibitors (NNRTI) and an integrase inhibitor. No PI affected XMRV production; even high concentrations of Ritonavir failed to inhibit the maturation of XMRV Gag polyproteins. Among the NRTI, NNRTI and integrase inhibitors used in this study, only AZT blocked XMRV infection and replication through inhibition of viral reverse transcription. This sensitivity of XMRV to AZT may be explained by the modest homology in the motif D sequences of HIV-1 and XMRV reverse transcriptases. If XMRV becomes established as an etiological agent for prostate cancer or other diseases, AZT may be useful for preventing or treating XMRV infections in humans.
Insights
The xenotropic murine leukemia virus-related virus (XMRV) is a human retrovirus. Only AZT (azidothymidine) effectively blocked XMRV infection by inhibiting reverse transcription, suggesting its potential use in treatment.
Area of Science:
- Virology
- Oncology
- Pharmacology
Background:
- Xenotropic murine leukemia virus-related virus (XMRV) is a human retrovirus linked to prostate cancer.
- Prostate cancer patients with XMRV often exhibit impaired RNase L activity.
Purpose of the Study:
- To evaluate the efficacy of 10 licensed anti-HIV-1 drugs against XMRV.
- To identify potential therapeutic agents for XMRV infections.
Main Methods:
- Testing of protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside RT inhibitors (NNRTI), and an integrase inhibitor.
- Assessing inhibition of XMRV production, maturation, and replication.
Main Results:
- No protease inhibitors showed activity against XMRV.
- Only AZT (azidothymidine) inhibited XMRV infection and replication by blocking reverse transcription.
- Similarities in reverse transcriptase motif D sequences between HIV-1 and XMRV may explain AZT sensitivity.
Conclusions:
- AZT is a potential therapeutic agent for XMRV infections.
- XMRV's etiological role in prostate cancer warrants further investigation.
- AZT could be valuable in preventing or treating human XMRV infections.
Related Concept Videos
Rabies
Antiviral Nucleoside Inhibitors
